Evidence map›Paper›PMID 24898094›Full record

ArticleThe Journal of membrane biology2014

In vivo characterization of the biodistribution profile of amphipol A8-35.

A Fernandez, C Le Bon, N Baumlin, F Giusti, G Crémel, J-L Popot, D Bagnard

Open access · greenAbstract read
In one paragraph

Article in The Journal of membrane biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Delivery of recombinant SARS-CoV-2 envelope protein into human cells.bioRxiv : the preprint server for biology · 2021
    Article
  3. Article
  4. In vivo studies investigating biodistribution of nanoparticle-encapsulated rhodamine B delivered via dissolving microneedles.Journal of controlled release : official journal of the Controlled Release Society · 2017
    Article
  5. Article
  6. Amphipols for each season.The Journal of membrane biology · 2014
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

A FernandezINSERM U1109, MN3t Lab, Labex Medalis, University of Strasbourg, 3 Avenue Molière, 67200, Strasbourg, France.
C Le Bon
N Baumlin
F Giusti
G Crémel
J-L Popot
D Bagnard
Université de Strasbourg · FRCentre National de la Recherche Scientifique · FRInserm · FRInstitut de Biologie Physico-Chimique · FR

Funding

Trapping membrane proteins with adjuvant-carrying amphipols for vaccine formulatiR01AI092129 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI COCCO, MELANIE J, DE LA MAZA, LUIS M · 2011 to 2014
$1.3M
NIAID NIH HHS R01 AI092129NIAID NIH HHS R01AI092129
6 · The paper itself

Abstract

Amphipols (APols) are polymeric surfactants that keep membrane proteins (MPs) water-soluble in the absence of detergent, while stabilizing them. They can be used to deliver MPs and other hydrophobic molecules in vivo for therapeutic purposes, e.g., vaccination or targeted delivery of drugs. The biodistribution and elimination of the best characterized APol, a polyacrylate derivative called A8-35, have been examined in mice, using two fluorescent APols, grafted with either Alexa Fluor 647 or rhodamine. Three of the most common injection routes have been used, intravenous (IV), intraperitoneal (IP), and subcutaneous (SC). The biodistribution has been studied by in vivo fluorescence imaging and by determining the concentration of fluorophore in the main organs. Free rhodamine was used as a control. Upon IV injection, A8-35 distributes rapidly throughout the organism and is found in most organs but the brain and spleen, before being slowly eliminated (10-20 days). A similar pattern is observed after IP injection, following a brief latency period during which the polymer remains confined to the peritoneal cavity. Upon SC injection, A8-35 remains essentially confined to the point of injection, from which it is only slowly released. An interesting observation is that A8-35 tends to accumulate in fat pads, suggesting that it could be used to deliver anti-obesity drugs.

Indexed as

Drug Delivery SystemsAdipose TissueAnimalsFemaleInjections, IntraperitonealInjections, IntravenousInjections, SubcutaneousMetabolic Clearance RateMiceMice, Inbred BALB CMice, NudeOrgan SpecificityPolymersPropylaminesTissue Distributionamphipol A8-35PolymersPropylamines

Identifiers

PMID24898094
PMCPMC4198491
OpenAlexW1986678880

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.